8-K: Werewolf Therapeutics Announces Positive Clinical Data and Second Quarter 2024 Financial Results

Werewolf Therapeutics reported encouraging clinical trial data for its WTX-124 and WTX-330 programs, along with its second quarter 2024 financial results.

Summary

• Werewolf Therapeutics announced its second quarter 2024 financial results and provided a business update, highlighting positive data from its ongoing clinical trials.
• The company presented data from the Phase 1/1b trial of WTX-124 at the ASCO Annual Meeting in June 2024, showing clinical activity and tolerability.
• WTX-124 monotherapy achieved three objective clinical responses, including one complete and two partial responses, in patients who had relapsed or were refractory to immune checkpoint inhibitor therapy.
• The combination of WTX-124 with pembrolizumab was also generally well-tolerated, with observed clinical activity in two melanoma patients.
• Initial data from the Phase 1 trial of WTX-330 showed therapeutically relevant exposure levels of the IL-12 prodrug, with one patient achieving an unconfirmed partial response.
• The company's cash and cash equivalents were $135.3 million as of June 30, 2024, which is expected to fund operations through at least the first quarter of 2026.
• Collaboration revenue for the second quarter of 2024 was $1.1 million, compared to $8.1 million for the same period in 2023, due to the substantial completion of obligations under the Jazz Pharmaceuticals agreement.
• Research and development expenses increased to $15.3 million in the second quarter of 2024, up from $9.6 million in 2023, driven by the progress of WTX-124 and WTX-330 clinical trials.
• The net loss for the second quarter of 2024 was $17.2 million, compared to a net loss of $5.1 million for the same period in 2023.

Sentiment

Score: 8

Explanation: The document presents positive clinical data and a strong cash position, indicating a positive outlook for the company. However, the increased net loss and decreased collaboration revenue temper the overall sentiment slightly.

Positives

• WTX-124 demonstrated strong clinical activity as a monotherapy, with a complete response and two partial responses.
• The combination of WTX-124 and pembrolizumab showed promising clinical activity and was well-tolerated.
• WTX-330 achieved significantly higher systemic drug concentrations of IL-12 prodrug compared to previous strategies.
• The company has a strong cash position, expected to fund operations through at least the first quarter of 2026.
• Preclinical programs for WTX-518 and WTX-712 are progressing well, showing promising results in mouse models.
• The company's PREDATOR platform shows promise in immune-mediated diseases.

Negatives

• Collaboration revenue decreased significantly from $8.1 million in Q2 2023 to $1.1 million in Q2 2024 due to the completion of the Jazz Pharmaceuticals agreement.
• Research and development expenses increased to $15.3 million in Q2 2024, up from $9.6 million in Q2 2023.
• The net loss for the second quarter of 2024 was $17.2 million, compared to a net loss of $5.1 million for the same period in 2023.

Risks

• The company faces risks inherent in the development of product candidates, including uncertainties in research activities and clinical trials.
• There are uncertainties regarding the availability and timing of results from preclinical studies and clinical trials.
• The company's ability to obtain regulatory approval for investigational new drug applications is not guaranteed.
• There is a risk that results from preclinical studies may not be predictive of later preclinical studies and clinical trials.
• The company's ability to manage cash resources and obtain additional funding is subject to uncertainty.

Future Outlook

The company expects to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor, and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. They anticipate updated data on WTX-124 in combination with pembrolizumab and the opening of expansion arms in the second half of 2024, and additional results from WTX-330 in the fourth quarter of 2024. The company believes its existing cash will fund operations through at least the first quarter of 2026.

Management Comments

• We believe the data recently presented from our WTX-124 and WTX-330 clinical programs displays the meaningful impact we can have on patients through our INDUKINE approach, and we are well positioned to advance both programs towards key inflection points in the coming quarters, said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf.
• We continue to focus on enrollment in these two clinical trials and look forward to providing additional clinical data updates as we look to address the unmet medical needs for cancer patients with late-stage disease.

Industry Context

This announcement is significant in the context of the broader immuno-oncology field, where companies are actively developing novel therapies to stimulate the body's immune system to fight cancer. Werewolf's INDUKINE platform and its conditionally activated molecules represent a unique approach to addressing the limitations of conventional proinflammatory immune therapies. The positive clinical data for WTX-124 and WTX-330 suggests that Werewolf is making progress in this competitive landscape.

Comparison to Industry Standards

• Werewolf's WTX-124 is being developed as a conditionally activated IL-2 therapy, which is a similar approach to companies like Nektar Therapeutics (Bempegaldesleukin) and Alkermes (Nemvaleukin alfa), though with a different activation mechanism. The complete response seen in the WTX-124 monotherapy arm is encouraging and compares favorably to early-stage data from other IL-2 based therapies.
• The 23-fold increase in systemic drug concentration of IL-12 prodrug with WTX-330 compared to previous IL-12 strategies is a significant improvement, addressing a key challenge in IL-12 based therapies, which have historically struggled with systemic toxicity. This compares favorably to other IL-12 programs that have not achieved such high concentrations with manageable toxicity.
• The company's cash runway through at least the first quarter of 2026 is a positive sign, providing financial stability for ongoing clinical development. This is comparable to other biotech companies at a similar stage of development, though the specific runway varies based on burn rate and funding.

Stakeholder Impact

• Shareholders will likely react positively to the encouraging clinical data and strong cash position.
• Employees may feel more secure due to the company's financial stability and progress in clinical trials.
• Patients with cancer may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will continue dose escalation for WTX-124 in combination with pembrolizumab.
• Expansion arms for WTX-124 are anticipated to open in the second half of 2024.
• Updated data on WTX-124 in combination with pembrolizumab is expected in the second half of 2024.
• Additional results from WTX-330 are expected in the fourth quarter of 2024.
• The company will continue to progress its preclinical programs for WTX-518 and WTX-712.

Key Dates

Keywords

Werewolf Therapeutics, WTX-124, WTX-330, INDUKINE, IL-2, IL-12, Cancer Therapy, Clinical Trials, Biopharmaceutical, Immunotherapy, Pembrolizumab, ASCO, PREDATOR platform